Author	Year	Country	Study type	Blinding	Sample method	Patient (n)	Lymph node (n)	Number of malignant nodes	Malignancy prevalence (%)	Diagnostic method	Cut-off value	Short-axis diameter (mm)	Male/ female	Age (year)	Reference standard	Time between standard reference and index test	Study Period	TP	FP	FN	TN	US equipment	Sensitivity (%)	Specificity (%)
Izumo et al 14	2014	Japan	Retrospective	Single blinded	Consecutive	30	75	42	56	3 classifications	Predominantly blue	15.0 median (5.0–50.0)	17/13	67.1±15.5	Pathology	Immediately	2014.1-2014.5	35	2	0	24	BF-UC260FW	100	92,3
He et al 23	2015	China	NR	Single blinded	NR	40	68	42	62	Strain ratio	32,07	17 median	26/14	65 (median)	Pathology	Immediately	2014.1-2015.1	37	5	5	21	EB-1970UK	88,1	80,8
Nakajima et al 24	2015	Japan	Retrospective	Double blinded	Consecutive	21	49	16	33	Stiff area ratio	0,311	8.44 (5.0–21.7)	15/6	63 (30–80)	Pathology or follow-up	Immediately	2013.5-2013.6	13	5	3	28	BF-UC260FW	81	85
Rozman et al 25	2015	Slovenia	Prospective	Double blinded	Consecutive	33	80	34	43	Strain ratio	8	11.1±4.5	25/8	67.5±8.2	Pathology or follow-up	Immediately	2013.8-2013.12	30	7	4	39	BF-UC180F	88,24	84,78
Korrungruang et al 26	2017	Thailand	Prospective	NR	NR	72	120	96	80	Strain ratio	2,5	18.8±7.9	41/31	58.3±12.5	Pathology or follow-up	Immediately	2015.7-2016.7	96	7	0	17	BF UC180F	100	66,7
Sun et al 27	2017	China	Retrospective	Double blinded	NR	56	68	35	51	5 classifications	Score: 4-5	19.92±9.09	32/24	56,07	Pathology or follow-up	Immediately	2014.1-2014.4	30	6	5	27	EB1970, Pentax, Japan	85,71	81,82
Gu et al 15	2017	China	Prospective	Double blinded	Consecutive	60	133	89	67	3 classifications	Predominantly blue	NR	49/11	62 (26-82)	Pathology	Immediately	2015.5.1-2015.5.31	42	7	0	13	BF-UC260FOL8 (Olympus) and EU-C2000 (Olympus)	100	65
Huang et al 28	2017	China	Retrospective	Double blinded	NR	47	78	33	42	3 classifications	Predominantly blue	NR	29/18	60.19±11.03	Pathology	Immediately	2015.6-2015.8	27	4	1	26	BF-UC260F and NA-201SX-4022	96	87
Ma et al 29	2018	China	Prospective	Single blinded	Consecutive	60	79	39	49	Blue color proportion	36,70%	NR	40/20	61,6	Pathology	Immediately	2015.7-2017.1	36	13	3	27	BF-UC260FW	92,3	67,5
Lin et al 30	2019	Taiwan	Retrospective	NR	NR	94	206	74	36	3 classifications	Predominantly blue	13.6 (2.0-56.3)	65/29	62.8 (20-97)	Pathology or follow-up	Immediately	2016.10-2017.7	48	19	5	90	EU-ME2 PREMIER PLUS	90,6	82,6
Roca et al 31	2019	Spain	Prospective	Double blinded	NR	27	42	18	43	3 classifications	Predominantly blue	15 ± 6	16/11	68±10	Pathology or follow-up	Immediately	NR	13	2	5	22	PENTAX, EB 1970 UK	73	92
Fournier et al 32	2019	France	Prospective	Double blinded	Consecutive	114	217	120	55	3 classifications	Predominantly blue	16.2 ± 8.5	80/34	60.2±12.2	Pathology	Immediately	2015.5-2016.8	67	16	10	34	OlympusBF UC 180F and OlympusEU-ME2	87	68
Verhoeven et al 33	2019	Netherlands	Prospective	Single blinded	NR	63	120	45	38	Mean histogram scoring strategy	78	9.95 (4–26)	39/24	64.3 (41–83)	Pathology or follow-up	Immediately	2015.7-2016.4	42	19	3	56	Hitachi Preirus Hi Vision processor and Pentax EB-1970UK echo-endoscopes	93	75
Çağlayan et al34	2020	Turkey	Prospective	Double blinded	Consecutive	119	221	93	42	Strain ratio	2,47	16.2±11.1	69/50	63.2±12.4	Pathology	Immediately	2016.1-2016.12	64	39	21	71	BF-UC180F	75	65
Uchimura et al35	2020	Japan	Retrospective	Double blinded	Consecutive	132	149	68	46	Stiffness area ratio	0,41	8	91/41	71 (median)	Pathology or follow-up	Immediately	2015.4-2018.11	60	16	8	65	BF-UC260FW	88	80
Gompelmann et al36	2020	Germany	Prospective	Double blinded	Not consecutive	65	77	55	71	3 classifications	Predominantly blue	NR	34/31	63 (52-82)	Pathology	Immediately	NR	25	4	10	8	NR	71	67
Verhoeven et al16	2020	Netherlands	Prospective	NR	NR	327	525	253	48	Strain histogram methord	78	12.3 (3-50)	200/127	66 (26-90)	Pathology or follow-up	Immediately	2016.6-2018.7	163	66	90	206	Pentax EB1970UK and EB19-J10U	64	76